{"id":10815,"date":"2018-07-01T05:00:33","date_gmt":"2018-07-01T09:00:33","guid":{"rendered":"https:\/\/medicarereport.org\/?p=10815"},"modified":"2018-06-29T10:14:09","modified_gmt":"2018-06-29T14:14:09","slug":"acceleron-blood-disease-drug-hits-goal-in-pivotal-clinical-trial","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=10815","title":{"rendered":"Acceleron blood disease drug hits goal in pivotal clinical trial"},"content":{"rendered":"<p>(By Adam Feurerstein for ST<em>A<\/em>T)<\/p>\n<p class=\"big-cap-wrap danger-zone\"><span class=\"big-cap\">Acceleron Pharma said Thursday that its experimental drug luspatercept significantly reduced the need for blood transfusions in patients with the blood disease myelodysplastic syndrome, meeting the primary goal of a Phase 3 clinical trial. <a href=\"https:\/\/www.statnews.com\/2018\/06\/28\/acceleron-celgene-blood-diseases-clinical-trials\/?_hsenc=p2ANqtz-_111Cl2bGvldkp5tnPYWnRX7D441J2x4KBQyyXrlvYKA8ckNY454trZ6-cfX5oeglnYUlmiELPsg8LG2s26aKFo4zFWQ&amp;_hsmi=64137520\">Continue reading article here&#8230;<\/a><\/span><\/p>\n<p class=\"big-cap-wrap danger-zone\"><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p class=\"big-cap-wrap danger-zone\">\n<pre>Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Adam Feurerstein for STAT) Acceleron Pharma said Thursday that its experimental drug luspatercept significantly reduced the need for blood<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-10815","post","type-post","status-publish","format-standard","hentry","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/10815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10815"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/10815\/revisions"}],"predecessor-version":[{"id":10816,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/10815\/revisions\/10816"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}